Cipla, a Rs.10,800 crore plus fifth largest Indian pharma company, has posted strong top line and bottom line growth during the first quarter ended June 2015 and its consolidated net profit went up sharply by 121 per cent to Rs.651 crore from Rs.295 crore in the corresponding period of last year. EBDITA also increased by 86.9 per cent to Rs.1,088 crore from Rs.582 crore. Its consolidated net sales has taken quantum jump of 42.7 per cent and reached at Rs.3,777 crore from Rs.2,647 crore. With impressive profit growth, its EPS moved up to Rs.8.10 from Rs.3.67 in the last period.

Despite strong performance, Cipla scrip declined by 3.5 per cent or Rs.25..85 on BSE in the morning session. Cipla reached at its yearly high level at Rs.752.45 on March 10, 2015. The company projected net sales growth of 20 per cent for the year 2015-16 with investments in R&D, consumer healthcare and biologics.

Cipla's international revenues worked out to 63 per cent of its total revenue and domestic sales stood at 37 per cent. Its formulations sales contributed 95 per cent and APIs 5 per cent to its revenue. Its exports of formulations increased by 78.5 per cent to Rs.2,174 crore from Rs.1,218 crore and exports of APIs increased by 47 per cent to Rs.206 crore from Rs.140 crore. The company launched salmeterol fluticasone in Romania and mometasone in Romania and Italy. Its in-licensing sales in South Africa with Teva moved strongly.

The company acquired 51 per cent stake in Quality Chemicals Ltd, in Uganda from the existing shareholders of company. It received US FDA approval for the world's first paediatric lopinavir and ritonavir oral pellets for the treatment of AIDS in infants and young children. The company is closely monitoring situation in Yemen.

Its domestic sales grew by 8.4 per cent to Rs.1,397 crore as against Rs.1,289 crore in the similar quarter of last year. The growth in domestic sales was largely on account of growth in respiratory, anti-infectives, cardiac and gastro intestinal therapies.

The company is taking steps towards capacity utilitisation and new capacity build for ARV products is expected to be completed by first half of next year. Currently, 200 formulation development projects are underway and it filed two formulation in US, 11 in Europe and 184 in international markets.

On standalone basis, Cipla's net sales increased by 44.3 per cent to Rs.3,467 crore from Rs.2,402 crore in the same period of last year. Its net profit moved up by 108 per cent to Rs.690 crore from Rs.332 crore.